JP2018522070A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522070A5
JP2018522070A5 JP2018525507A JP2018525507A JP2018522070A5 JP 2018522070 A5 JP2018522070 A5 JP 2018522070A5 JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018522070 A5 JP2018522070 A5 JP 2018522070A5
Authority
JP
Japan
Prior art keywords
composition
cholesten
composition according
steroid
cataract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522070A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044337 external-priority patent/WO2017019808A1/en
Publication of JP2018522070A publication Critical patent/JP2018522070A/ja
Publication of JP2018522070A5 publication Critical patent/JP2018522070A5/ja
Pending legal-status Critical Current

Links

JP2018525507A 2015-07-27 2016-07-27 白内障の処置用組成物 Pending JP2018522070A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562197477P 2015-07-27 2015-07-27
US62/197,477 2015-07-27
US201562202518P 2015-08-07 2015-08-07
US62/202,518 2015-08-07
US201562252120P 2015-11-06 2015-11-06
US62/252,120 2015-11-06
US201662295267P 2016-02-15 2016-02-15
US62/295,267 2016-02-15
PCT/US2016/044337 WO2017019808A1 (en) 2015-07-27 2016-07-27 Compositions for the treatment of cataracts

Publications (2)

Publication Number Publication Date
JP2018522070A JP2018522070A (ja) 2018-08-09
JP2018522070A5 true JP2018522070A5 (enExample) 2019-06-20

Family

ID=56616065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525507A Pending JP2018522070A (ja) 2015-07-27 2016-07-27 白内障の処置用組成物

Country Status (7)

Country Link
US (2) US10398709B2 (enExample)
EP (1) EP3328389A1 (enExample)
JP (1) JP2018522070A (enExample)
CN (1) CN108472303A (enExample)
AU (1) AU2016298951B2 (enExample)
CA (1) CA2993196A1 (enExample)
WO (1) WO2017019808A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
US20180250313A1 (en) * 2015-09-08 2018-09-06 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
IL298681A (en) 2016-08-02 2023-01-01 Univ Virginia Commonwealth Preparations
GB2581656A (en) * 2017-11-17 2020-08-26 Piraee Mahmood Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
EP3813794A4 (en) * 2018-06-27 2022-07-13 Cellix Bio Private Limited COMPOSITIONS AND METHODS OF TREATMENT EYE DISEASES
EP3955916A4 (en) * 2019-04-19 2023-01-25 Buck Institute for Research on Aging 25-HYDROXYCHOLESTEROL (25HC), A CRYAB AGGREGATION INHIBITOR, IS A NEW SENOLYTIC
MX2023005451A (es) * 2020-11-11 2023-05-23 Scherer Technologies Llc R P Capsulas de gel blando de liberacion retardada.
MX2021009520A (es) * 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
KR20240046546A (ko) * 2021-08-18 2024-04-09 광저우 오쿠순 옵탈믹 바이오테크놀로지 캄파니 리미티드 스테로이드의 비문증 예방 및/또는 치료 약물 제조에 있어서의 용도
CA3228588A1 (en) * 2021-08-18 2023-02-23 Yandong Wang Pharmaceutical composition, preparation method therefor and application thereof
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
EP4467144A4 (en) 2022-01-21 2026-01-21 Senju Usa Inc AQUEOUS LIQUID FORMULATION
JP2026503212A (ja) * 2022-12-23 2026-01-28 デュレクト コーポレーション 25-ヒドロキシ-コレスタ-5-エン-3-硫酸コリン、その製剤、並びにこれを調製する方法及び医学的使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4192827A (en) 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US20020132758A1 (en) 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
CA2878946A1 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
MX2016007377A (es) * 2013-12-05 2016-10-13 Univ Miami Composiciones y metodos para reducir la presion intraocular.
CA2958868A1 (en) * 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders
WO2016029197A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye

Similar Documents

Publication Publication Date Title
US11439590B2 (en) Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
RU2632107C2 (ru) Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник
JP2001510170A (ja) 光力学的治療法において血管新生抑制性ステロイド類を使用する方法・用途
CA3023243C (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
JP2018522070A (ja) 白内障の処置用組成物
US20160243031A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
CN101175487B (zh) 依布硒啉的制药用途
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び/又はベタメタゾンの医薬組成物
US20190111045A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
WO2017179003A1 (en) Topical compositions for ophthalmic and otic use
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
JP2011144111A (ja) 軸性近視の予防または治療剤
CN110664829A (zh) 京尼平苷在制备抗肺纤维化药物中的应用
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および/または近視進行抑制剤
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
JP2004256524A (ja) ステロイド副作用抑制組成物
CN1239161C (zh) 可用于治疗干眼疾病的类固醇
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
WO2004069822A1 (ja) ステロイド副作用抑制組成物
JP2019038783A (ja) ドライアイの治療剤
WO2007148744A1 (ja) フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
WO2025192685A1 (ja) デキサメタゾンを含む医薬組成物
CN122055145A (zh) 用于治疗原发性胆汁性胆管炎的埃拉菲布拉诺
CN117959316A (zh) 一种包含恩格列净的药物组合物及其制备方法与制药用途